Loss of enteric dopaminergic neurons and associated changes in colon motility in an MPTP mouse model of Parkinson's disease - PubMed (original) (raw)
Loss of enteric dopaminergic neurons and associated changes in colon motility in an MPTP mouse model of Parkinson's disease
Grant Anderson et al. Exp Neurol. 2007 Sep.
Abstract
Gastrointestinal (GI) dysfunction is the most common non-motor symptom of Parkinson's disease (PD). Symptoms of GI dysmotility include early satiety and nausea from delayed gastric emptying, bloating from poor small bowel coordination, and constipation and defecatory dysfunction from impaired colonic transit. Understanding the pathophysiology and treatment of these symptoms in PD patients has been hampered by the lack of investigation into GI symptoms and pathology in PD animal models. We report that the prototypical parkinsonian neurotoxin, MPTP (1-methyl 4-phenyl 1,2,3,6-tetrahydropyridine), is a selective dopamine neuron toxin in the enteric nervous system (ENS). When examined 10 days after treatment, there was a 40% reduction of dopamine neurons in the ENS of C57Bl/6 mice administered MPTP (60 mg/kg). There were no differences in the density of cholinergic or nitric oxide neurons. Electrophysiological recording of neural-mediated muscle contraction in isolated colon from MPTP-treated animals confirmed a relaxation defect associated with dopaminergic degeneration. Behaviorally, MPTP induced a transient increase in colon motility, but no changes in gastric emptying or small intestine transit. These results provide the first comprehensive assessment of gastrointestinal pathophysiology in an animal model of PD. They provide insight into the impact of dopaminergic dysfunction on gastrointestinal motility and a benchmark for assessment of other PD model systems.
Figures
Figure 1. MPTP causes dopamine neuron loss in the ENS
A. Bar graph indicating the number of TH-positive neurons per ganglion in the myenteric plexus of the distal ileum in mice ten days after treatment with saline (N=8) or MPTP (60 mg/kg; N=7). *p < 0.05. B. Photograph of the myenteric plexus from mouse ileum immunostained for TH. The arrow denotes a TH-positive neuron shown at higher magnification in the inset. The dashed lines outline two ganglia.
Figure 2. MPTP does not affect numbers of nitric oxide or cholinergic neurons in the ENS
A. Bar graph indicating the number of NADPH-diaphorase-positive neurons per mm2 in the myenteric plexus of the distal ileum in mice ten days after treatment with saline (N=7) or MPTP ( N=7). B. Bar graph indicating the number of ChAT-positive neurons per mm2 in the myenteric plexus of the distal ileum in mice ten days after treatment with saline (N=4) or MPTP (N=7). C. Photograph of the myenteric plexus from mouse ileum immunostained for ChAT (brown) and histochemically stained for NADPH-diaphorase (blue). Note the relative abundance of both neuron types as compared to TH-positive cells. Inset shows a higher magnification view of one ChAT-positive and one NADPH-positive neuron.
Figure 3. Dopamine neuron loss causes impaired neural-mediated relaxation of proximal colon
A. Representative tracing of EFS-induced muscle contraction in circular muscle preparations from a saline- and an MPTP-treated mouse. B. Compiled data from 4 experiments like that shown in A quantifying enhanced contraction in MPTP-treated mice. C. Representative tracing of EFS-induced muscle relaxation in longitudinal muscle preparations from a saline- and an MPTP-treated mouse. D. Compiled data from 4 experiments like that shown in C quantifying impaired relaxation in MPTP-treated mice. *p <0.05.
Figure 4. Transiently increased colon motility after MPTP treatment
A. Stool frequency was dramatically higher in MPTP-treated animals 2-3 days after treatment, but was similar to saline-treated controls by 8-10 days after MPTP. (N=8 per group). *p < 0.05. B. Solid matter in stool correlates with stool frequency (R = −0.69). Since the colon functions to remove water, this confirms the utility of one-hour stool frequency as a measure of colon transit time. Data are from multiple one-hour collection periods from saline- (N=14) and MPTP-treated (N=12) animals across the entire time course of the experiment (from prior to injection through 10 days after).
Figure 5. Gastric emptying is unaffected by MPTP
A. Time course of gastric dye retention in saline- and MPTP-treated animals ten days after treatment. Amount of dye remaining in the stomach was normalized between the zero and 1 hour time points. (N=3 per group per time point). B. The amount of solid food remaining in the stomach after 2 hours was no different between groups (N=13 per group).
Figure 6. Small intestinal transit is unaffected by MPTP
Distance from the pylorus to the dye front is plotted against time. (N=3 per group per time point).
Comment in
- The role of MPTP in Parkinson's disease: connecting brain and gut?
Goetze O, Woitalla D. Goetze O, et al. Exp Neurol. 2008 Apr;210(2):281-5. doi: 10.1016/j.expneurol.2008.01.004. Epub 2008 Jan 19. Exp Neurol. 2008. PMID: 18279853 Review. No abstract available.
Similar articles
- Delayed gastric emptying and enteric nervous system dysfunction in the rotenone model of Parkinson's disease.
Greene JG, Noorian AR, Srinivasan S. Greene JG, et al. Exp Neurol. 2009 Jul;218(1):154-61. doi: 10.1016/j.expneurol.2009.04.023. Epub 2009 May 3. Exp Neurol. 2009. PMID: 19409896 Free PMC article. - Impairment of Nrf2- and Nitrergic-Mediated Gastrointestinal Motility in an MPTP Mouse Model of Parkinson's Disease.
Sampath C, Kalpana R, Ansah T, Charlton C, Hale A, Channon KM, Srinivasan S, Gangula PR. Sampath C, et al. Dig Dis Sci. 2019 Dec;64(12):3502-3517. doi: 10.1007/s10620-019-05693-5. Epub 2019 Jun 11. Dig Dis Sci. 2019. PMID: 31187328 Free PMC article. - Alteration of dopaminergic markers in gastrointestinal tract of different rodent models of Parkinson's disease.
Tian YM, Chen X, Luo DZ, Zhang XH, Xue H, Zheng LF, Yang N, Wang XM, Zhu JX. Tian YM, et al. Neuroscience. 2008 May 15;153(3):634-44. doi: 10.1016/j.neuroscience.2008.02.033. Epub 2008 Feb 29. Neuroscience. 2008. PMID: 18420351 - [A mouse model of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced parkinsonism: effect of norepinephrine terminal destruction].
Nishi K, Kondo T, Narabayashi H. Nishi K, et al. No To Shinkei. 1987 Jul;39(7):663-72. No To Shinkei. 1987. PMID: 3314916 Review. Japanese. - Gastric motor dysfunctions in Parkinson's disease: Current pre-clinical evidence.
Pellegrini C, Antonioli L, Colucci R, Ballabeni V, Barocelli E, Bernardini N, Blandizzi C, Fornai M. Pellegrini C, et al. Parkinsonism Relat Disord. 2015 Dec;21(12):1407-14. doi: 10.1016/j.parkreldis.2015.10.011. Epub 2015 Oct 21. Parkinsonism Relat Disord. 2015. PMID: 26499757 Review.
Cited by
- Differential regional and subtype-specific vulnerability of enteric neurons to mitochondrial dysfunction.
Viader A, Wright-Jin EC, Vohra BP, Heuckeroth RO, Milbrandt J. Viader A, et al. PLoS One. 2011;6(11):e27727. doi: 10.1371/journal.pone.0027727. Epub 2011 Nov 16. PLoS One. 2011. PMID: 22110743 Free PMC article. - Autonomic nervous system involvement in the giant axonal neuropathy (GAN) KO mouse: implications for human disease.
Armao D, Bailey RM, Bouldin TW, Kim Y, Gray SJ. Armao D, et al. Clin Auton Res. 2016 Aug;26(4):307-13. doi: 10.1007/s10286-016-0365-7. Epub 2016 Jul 1. Clin Auton Res. 2016. PMID: 27369358 Free PMC article. - Neurogenic bowel dysfunction in patients with spinal cord injury, myelomeningocele, multiple sclerosis and Parkinson's disease.
Awad RA. Awad RA. World J Gastroenterol. 2011 Dec 14;17(46):5035-48. doi: 10.3748/wjg.v17.i46.5035. World J Gastroenterol. 2011. PMID: 22171138 Free PMC article. Review. - Behavioral phenotyping of mouse models of Parkinson's disease.
Taylor TN, Greene JG, Miller GW. Taylor TN, et al. Behav Brain Res. 2010 Jul 29;211(1):1-10. doi: 10.1016/j.bbr.2010.03.004. Epub 2010 Mar 6. Behav Brain Res. 2010. PMID: 20211655 Free PMC article. Review. - Neurochemical phenotypes of myenteric neurons in the rhesus monkey.
Noorian AR, Taylor GM, Annerino DM, Greene JG. Noorian AR, et al. J Comp Neurol. 2011 Dec 1;519(17):3387-401. doi: 10.1002/cne.22679. J Comp Neurol. 2011. PMID: 21618236 Free PMC article.
References
- Abbott RD, Petrovitch H, White LR, Masaki KH, Tanner CM, Curb JD, Grandinetti A, Blanchette PL, Popper JS, Ross GW. Frequency of bowel movements and the future risk of Parkinson's disease. Neurology. 2001;57:456–462. - PubMed
- Ashraf W, Wszolek ZK, Pfeiffer RF, Normand M, Maurer K, Srb F, Edwards LL, Quigley EM. Anorectal function in fluctuating (on-off) Parkinson's disease: evaluation by combined anorectal manometry and electromyography. Mov Disord. 1995;10:650–657. - PubMed
- Betarbet R, Canet-Aviles RM, Sherer TB, Mastroberardino PG, McLendon C, Kim JH, Lund S, Na HM, Taylor G, Bence NF, Kopito R, Seo BB, Yagi T, Yagi A, Klinefelter G, Cookson MR, Greenamyre JT. Intersecting pathways to neurodegeneration in Parkinson's disease: effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system. Neurobiol Dis. 2006;22:404–420. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- K08 NS048858-03/NS/NINDS NIH HHS/United States
- K08 DK067045/DK/NIDDK NIH HHS/United States
- K08 NS048858/NS/NINDS NIH HHS/United States
- R24 DK064399/DK/NIDDK NIH HHS/United States
- K08 DK067045-04/DK/NIDDK NIH HHS/United States
- DK064399/DK/NIDDK NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources